Evidence map›Paper›PMID 37345484›Full record

ArticleHaematologica2024

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.

Tracy Murphy, Jinfeng Zou, Andrea Arruda, Ting Ting Wang, Zhen Zhao, Yangqiao Zheng, Vikas Gupta, Dawn Maze, Caroline McNamara, Mark D Minden and 8 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Mutations and MRD: clinical implications of clonal ontogeny.Hematology. American Society of Hematology. Education Program · 2024
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Tracy MurphyPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Jinfeng ZouPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Andrea ArrudaPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Ting Ting WangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Zhen ZhaoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Yangqiao ZhengPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Vikas GuptaPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Dawn MazePrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Caroline McNamaraRoyal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Mark D MindenPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Aaron SchimmerPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Hassan SibaiPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Karen YeePrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Jose-Mario Capo-ChichiPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON.
Tracy StockleyPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON.
Andre SchuhPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Scott V BratmanPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario.
Steven M ChanPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario. steven.chan@uhnresearch.ca.
University Health Network · CAPrincess Margaret Cancer Centre · CARoyal Brisbane and Women's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Isocitrate DehydrogenaseLeukemia, Myeloid, AcuteHumansMutationNeoplasm, ResidualPrognosisRNA Splicing FactorsIsocitrate DehydrogenaseRNA Splicing Factors

Identifiers

PMID37345484
PMCPMC10828788
OpenAlexW4381597464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.